Literature DB >> 28440019

Cervical cancer risk and impact of Pap-based screening in HIV-positive women on antiretroviral therapy in Johannesburg, South Africa.

Eliane Rohner1, Mazvita Sengayi2, Bridgette Goeieman3, Pamela Michelow4,5, Cynthia Firnhaber3,6, Mhairi Maskew7, Julia Bohlius1.   

Abstract

Data on invasive cervical cancer (ICC) incidence in HIV-positive women and the effect of cervical cancer screening in sub-Saharan Africa are scarce. We estimated i) ICC incidence rates in women (≥18 years) who initiated antiretroviral therapy (ART) at the Themba Lethu Clinic (TLC) in Johannesburg, South Africa, between 2004 and 2011 and ii) the effect of a Pap-based screening program. We included 10,640 women; median age at ART initiation: 35 years [interquartile range (IQR) 30-42], median CD4 count at ART initiation: 113 cells/µL (IQR 46-184). During 27,257 person-years (pys), 138 women were diagnosed with ICC; overall incidence rate: 506/100,000 pys [95% confidence interval (CI) 428-598]. The ICC incidence rate was highest (615/100,000 pys) in women who initiated ART before cervical cancer screening became available in 04/2005 and was lowest (260/100,000 pys) in women who initiated ART from 01/2009 onward when the cervical cancer screening program and access to treatment of cervical lesions was expanded [adjusted hazard ratio (aHR) 0.42, 95% CI 0.20-0.87]. Advanced HIV/AIDS stage (4 versus 1, aHR 1.95, 95% CI 1.17-3.24) and middle age at ART initiation (36-45 versus 18-25 years, aHR 2.51, 95% CI 1.07-5.88) were risk factors for ICC. The ICC incidence rate substantially decreased with the implementation of a Pap-based screening program and improved access to treatment of cervical lesions. However, the risk of developing ICC after ART initiation remained high. To inform and improve ICC prevention and care for HIV-positive women in sub-Saharan Africa, implementation and monitoring of cervical cancer screening programs are essential.
© 2017 UICC.

Entities:  

Keywords:  HIV; South Africa; cervical cancer; cohort study; screening

Mesh:

Substances:

Year:  2017        PMID: 28440019      PMCID: PMC5504282          DOI: 10.1002/ijc.30749

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  35 in total

1.  ACOG Practice Bulletin No. 117: Gynecologic care for women with human immunodeficiency virus.

Authors: 
Journal:  Obstet Gynecol       Date:  2010-12       Impact factor: 7.661

2.  Incidence of invasive cervical cancer in a cohort of HIV-seropositive women before and after the introduction of highly active antiretroviral therapy.

Authors:  M Dorrucci; B Suligoi; D Serraino; U Tirelli; G Rezza
Journal:  J Acquir Immune Defic Syndr       Date:  2001-04-01       Impact factor: 3.731

3.  Cohort profile: the Themba Lethu Clinical Cohort, Johannesburg, South Africa.

Authors:  Matthew P Fox; Mhairi Maskew; A Patrick MacPhail; Lawrence Long; Alana T Brennan; Daniel Westreich; William B MacLeod; Pappie Majuba; Ian M Sanne
Journal:  Int J Epidemiol       Date:  2012-03-20       Impact factor: 7.196

Review 4.  Infrastructure requirements for human papillomavirus vaccination and cervical cancer screening in sub-Saharan Africa.

Authors:  Rengaswamy Sankaranarayanan; Rose Anorlu; Ghislain Sangwa-Lugoma; Lynette A Denny
Journal:  Vaccine       Date:  2013-12-29       Impact factor: 3.641

Review 5.  Assessing the impact of HAART on the incidence of defining and non-defining AIDS cancers among patients with HIV/AIDS: a systematic review.

Authors:  Ricardo Ney Oliveira Cobucci; Paulo Henrique Lima; Pollyana Carvalho de Souza; Vanessa Viana Costa; Maria da Conceição de Mesquita Cornetta; José Veríssimo Fernandes; Ana Katherine Gonçalves
Journal:  J Infect Public Health       Date:  2014-10-05       Impact factor: 3.718

6.  Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults.

Authors: 
Journal:  J Natl Cancer Inst       Date:  2000-11-15       Impact factor: 13.506

7.  Cancer incidence among HIV-positive women in British Columbia, Canada: Heightened risk of virus-related malignancies.

Authors:  K A Salters; A Cescon; W Zhang; G Ogilvie; M C M Murray; A Coldman; J Hamm; C G Chiu; J S G Montaner; S M Wiseman; D Money; N Pick; R S Hogg
Journal:  HIV Med       Date:  2015-08-12       Impact factor: 3.180

8.  Highly active antiretroviral therapy and cervical dysplasia in HIV-positive women in South Africa.

Authors:  Cynthia Firnhaber; Daniel Westreich; Doreen Schulze; Sophie Williams; Maureen Siminya; Pam Michelow; Simon Levin; Mark Faesen; Jennifer S Smith
Journal:  J Int AIDS Soc       Date:  2012-06-07       Impact factor: 5.396

9.  Nelfinavir, an HIV protease inhibitor, induces apoptosis and cell cycle arrest in human cervical cancer cells via the ROS-dependent mitochondrial pathway.

Authors:  Tong Xiang; Lanying Du; Petra Pham; Bo Zhu; Shibo Jiang
Journal:  Cancer Lett       Date:  2015-04-29       Impact factor: 9.756

10.  The distribution of sexually-transmitted Human Papillomaviruses in HIV positive and negative patients in Zambia, Africa.

Authors:  Christopher Ng'andwe; John J Lowe; Paula J Richards; Lara Hause; Charles Wood; Peter C Angeletti
Journal:  BMC Infect Dis       Date:  2007-07-16       Impact factor: 3.090

View more
  6 in total

1.  HIV-positive women have higher risk of human papilloma virus infection, precancerous lesions, and cervical cancer.

Authors:  Gui Liu; Monisha Sharma; Nicholas Tan; Ruanne V Barnabas
Journal:  AIDS       Date:  2018-03-27       Impact factor: 4.177

Review 2.  Cancer in adolescents and young adults living with HIV.

Authors:  Julia Bohlius; Caroline Foster; Gita Naidu; Mazvita Sengayi; Anna Turkova
Journal:  Curr Opin HIV AIDS       Date:  2018-05       Impact factor: 4.283

Review 3.  Recent advances in cancer outcomes in HIV-positive smokers.

Authors:  Sabina Ranjit; Santosh Kumar
Journal:  F1000Res       Date:  2018-06-11

4.  Cost-Effectiveness of Cervical Cancer Screening in Women Living With HIV in South Africa: A Mathematical Modeling Study.

Authors:  Nicole G Campos; Naomi Lince-Deroche; Carla J Chibwesha; Cynthia Firnhaber; Jennifer S Smith; Pam Michelow; Gesine Meyer-Rath; Lise Jamieson; Suzette Jordaan; Monisha Sharma; Catherine Regan; Stephen Sy; Gui Liu; Vivien Tsu; Jose Jeronimo; Jane J Kim
Journal:  J Acquir Immune Defic Syndr       Date:  2018-10-01       Impact factor: 3.731

5.  Spatiotemporal modelling and mapping of cervical cancer incidence among HIV positive women in South Africa: a nationwide study.

Authors:  Dhokotera Tafadzwa; Riou Julien; Bartels Lina; Rohner Eliane; Chammartin Frederique; Johnson Leigh; Singh Elvira; Olago Victor; Sengayi-Muchengeti Mazvita; Egger Matthias; Bohlius Julia; Konstantinoudis Garyfallos
Journal:  Int J Health Geogr       Date:  2021-06-29       Impact factor: 3.918

6.  Costs and cost-effectiveness of LEEP versus cryotherapy for treating cervical dysplasia among HIV-positive women in Johannesburg, South Africa.

Authors:  Naomi Lince-Deroche; Craig van Rensburg; Jaqueline Roseleur; Busola Sanusi; Jane Phiri; Pam Michelow; Jennifer S Smith; Cindy Firnhaber
Journal:  PLoS One       Date:  2018-10-11       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.